Literature DB >> 15942499

Enucleation with primary implant insertion for treatment of recalcitrant endophthalmitis and panophthalmitis.

Ari D Abel1, Dale R Meyer.   

Abstract

PURPOSE: A prevalent conception exists that a two-stage operation (i.e., primary enucleation or evisceration with delayed secondary orbital implant insertion) is necessary when enucleation is required for recalcitrant endophthalmitis or panophthalmitis. The purpose of this study was to assess the utility of single-stage enucleation and primary reconstruction in this setting.
METHODS: In a retrospective interventional case series, 22 consecutive patients with advanced endophthalmitis or panophthalmitis refractory to prior medical treatment underwent enucleation and primary implant placement by a single surgeon between 1991 and 2001. Eleven patients received hydroxyapatite implants; 11 patients received silicone implants. All patients were treated during surgery with intravenous antibiotics. All patients were evaluated for persistent local or systemic infection, implant exposure, extrusion, and successful fitting of their prostheses.
RESULTS: No cases of persistent orbital cellulitis or meningitis occurred in any of the patients. Two patients with silicone orbital implants had extrusions; one was successfully managed with a secondary dermis-fat graft, and another patient who refused additional treatment was allowed to heal by secondary intention after the implant was removed. None of the patients with hydroxyapatite orbital implants had complications. All patients (20/20) who elected to undergo prosthetic fitting were successfully fit with prostheses. One patient elected not to pursue prosthetic fitting. One patient died of unrelated causes before a prosthesis could be fit. There were no objective findings to preclude successful fitting in either case.
CONCLUSIONS: This study suggests that enucleation with primary orbital reconstruction and implant insertion for recalcitrant, fulminant ocular infection is an acceptable and advantageous treatment strategy. The risks and expenses associated with two separate surgeries are decreased, hospitalization time is potentially reduced, and subsequent rehabilitation can be initiated in a more timely fashion.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15942499     DOI: 10.1097/01.iop.0000159174.80985.e2

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  7 in total

Review 1.  Imaging of orbital infectious and inflammatory disease in children.

Authors:  Usha D Nagaraj; Bernadette L Koch
Journal:  Pediatr Radiol       Date:  2021-05-12

2.  The results of evisceration with primary porous implant placement in patients with endophthalmitis.

Authors:  Young-Gun Park; Ji-Sun Paik; Suk-Woo Yang
Journal:  Korean J Ophthalmol       Date:  2010-10-05

3.  Bacillus cereus panophthalmitis with delayed dermis fat graft.

Authors:  Donovan S Reed; Aliza Epstein; Eloisa Crouse; Marie Somogyi
Journal:  Proc (Bayl Univ Med Cent)       Date:  2021-03-05

4.  Dermis-fat grafts and enucleation in Ghanaian children: 5 years' experience.

Authors:  V A Essuman; N N Tagoe; T A Ndanu; C T Ntim-Amponsah
Journal:  Ghana Med J       Date:  2014-12

5.  Prevention of Evisceration or Enucleation in Endogenous Bacterial Panophthalmitis with No Light Perception and Scleral Abscess.

Authors:  Kuan-Jen Chen; Yen-Po Chen; An-Ning Chao; Nan-Kai Wang; Wei-Chi Wu; Chi-Chun Lai; Tun-Lu Chen
Journal:  PLoS One       Date:  2017-01-05       Impact factor: 3.240

6.  Outcomes of evisceration or enucleation by resident trainees in patients with recalcitrant endophthalmitis or panophthalmitis.

Authors:  Wannaporn Tianthong; Orapan Aryasit
Journal:  Medicine (Baltimore)       Date:  2022-07-29       Impact factor: 1.817

7.  A Case of Escherichia coli Endogenous Panophthalmitis and Orbital Cellulitis With Normal Workup for Primary Focus.

Authors:  Fadi F Hassanin; Sahar Elkhamary; Rawan Al Thaqib; Diego Strianese
Journal:  Cureus       Date:  2021-05-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.